CDK7 Inhibitor Compounds with Improved Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cyclin-dependent kinase (CDK) inhibitors face challenges such as low bioavailability when administered orally and limited effectiveness against various diseases, including cancer, inflammatory, and infectious conditions.
Innovation Solution
Development of compounds with specific structural formulas that inhibit CDK7, particularly CDK7/MAT1/CycH complexes, suitable for oral administration, formulated into pharmaceutical compositions for treating proliferative, infectious, immunological, and inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current CDK inhibitors are administered orally, then they can be delivered systemically, but their bioavailability is low
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of CDK inhibitors to optimize their pharmacokinetic properties. Specifically, the compounds are designed with improved molecular characteristics that enhance oral bioavailability while maintaining CDK inhibitory activity, resolving the contradiction between oral administration feasibility and low bioavailability
Solution Approach 2:
The invention uses local quality by introducing specific functional groups and structural modifications at particular positions of the inhibitor molecules. These localized structural changes improve absorption and bioavailability without compromising the overall inhibitory function against CDK targets
2Reliability
If CDK7 is inhibited to treat cancer and viral infections, then therapeutic effectiveness is improved, but selectivity between cancer cells and normal cells must be maintained
Solution Approach 1:
The patent applies local quality by designing compounds that selectively target CDK7 in cancer and viral contexts. The molecular structure is optimized to interact specifically with aberrant CDK7 complexes in diseased cells while sparing normal physiological processes, thereby achieving therapeutic effectiveness with appropriate selectivity
Solution Approach 2:
The invention employs partial action by achieving sufficient CDK7 inhibition to treat disease without complete suppression of all CDK7 activity. This allows therapeutic effectiveness against cancer and viral infections while preserving essential housekeeping functions that depend on CDK7, thus maintaining cellular selectivity
3Adaptability or versatility
If broad-spectrum disease treatment is achieved through CDK7 inhibition, then versatility is improved, but understanding of specific disease mechanisms must be comprehensive
Solution Approach 1:
The patent applies universality by developing CDK7 inhibitors with broad-spectrum activity against multiple disease types including cancer, viral infections, and inflammatory conditions. The compounds are designed to target the conserved CDK7 kinase domain across different pathological contexts, enabling versatile therapeutic application while relying on shared CDK7-dependent mechanisms in diverse diseases
Data Source
AI summary
The present invention relates to compounds having cyclin-dependent kinase (CDK)-inhibitory functions and/or pharmaceutically acceptable salts thereof, the use of these compounds as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing such compounds.